Cobenfy (xanomeline/trospium chloride; formerly KarXT) was approved for schizophrenia in adults by the Food and Drug Administration in late September. The drug has a novel mechanism of action, which is the first for schizophrenia in several decades. Cobenfy targets cholinergic receptors instead of balancing levels of dopamine and serotonin, which is what conventional atypical antipsychotics
Read More
Stock market today; Wall Street drifts toward its longest weekly winning streak of the year
U.S. stocks are hanging around their records as they close out another winning week…Read More
November 16, 2024
No Comments
